Journal of
eISSN: 2373-6453
Submit manuscript...
Editorial Volume 9 Issue 2
SARS-CoV-2 (COVID-19) vaccination, affected on post-acute-COVID-19-sequelae symptoms (long COVID-19)
Attapon Cheepsattayakorn,1,2 
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Ruangrong Cheepsattayakorn,3 Porntep Siriwanarangsun,
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
1Faculty of Medicine, Western University, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand
Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100, Thailand, Tel 66 53 140767, 66 53 276364, Fax 66 53 140773, 66 53 273590
Received: July 04, 2022 | Published: July 5, 2022
Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun p. SARS-CoV-2 (COVID-19) vaccination, affected on post-acute-COVID-19-sequelae symptoms (long COVID-19). J Hum Virol Retroviral. 2022;9(2):35. DOI: 10.15406/jhvrv.2022.09.00244
Editorial
Currently, few prospective data that explore the biological mechanisms of the effect of SARS-CoV-2 (COVID-19) vaccination on the persistent symptoms, “ long-COVID 19 ” or “ post-acute sequelae of COVID (PASC) ”, including compared antibody dynamics between those with and without PASC.1,2 PASC is defined by symptoms persisting more than 4 weeks after a confirmed or probable COVID-19, without any confirmed alternative diagnosis.1 Around 52.8 % of the patients reported a global effect on symptoms after the vaccine injection, corresponding to a worsening in around 31 % and an improvement in around 21.8 %.1 No differences based on the vaccine type used were detected.1 Fear of worsening PASC symptoms (55.9 %) were the most common reasons for the SARS-CoV-2 (COVID-19) vaccination postponing.1 Around 58.9 % of the enrolled subjects developed PASC after at least 3 months of follow-up.2 Age, sex, obesity status, and time since illness onset of the participants have no significantly statistical differences.2 Among PASC participants, they revealed the median half-life of RBD- and spike-binding IgG levels of 181 (95 % CI : 147-230); and 233 (95 % CI : 183-324) days, whereas among those without PASC demonstrated 144 (95 % CI : 113-196) and 170 (95 % CI: 125-252) days, respectively.2
Conclusion
In conclusion, the majority of PASC patients were well tolerated to SARS-CoV-2 (COVID-19) vaccine and have good immunogenicity. However, further investigations are urgently needed to confirm the COVID-19-vaccine-related strong evidence on improvement of PASC symptoms.
Acknowledgments
None.
Conflicts of interest
None.
References
- Scherlinger M, Pijnenburg L, Chatelus E, et al. Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG Study. Vaccines. 2022;10(1)46.
- Wynberg E, Han AX, Boyd A, et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): a prospective cohort study. Vaccine. 2022. In Press.
©2022 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.